F. Hoffmann-La Roche Announces Half Year Results 2022

On July 21, 2022 F. Hoffmann-La Roche Ltd. (hereafter "Roche") [Head Office: Basel, Switzerland. CEO: Severin Schwan] reported its half year results 2022 (January 1 – June 30, 2022) (Press release, Hoffmann-La Roche, JUL 21, 2022, View Source [SID1234616855]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Roche owns 59.89% of Chugai’s outstanding shares (61.14% of voting rights) as of the end of June 2022.

Its investor update and presentation materials can be found on its website (View Source).
Chugai’s performance for the period of January 1 to June 30, 2022 is included in the announced Roche Group’s results.